Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
- Citation:
- Epigenetics vol 17 (12) 1715-1725
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 12
- Parents:
- None
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882 , U24CA196171, UG1CA233180, UG1CA233328, UG1CA233339, UG1CA233373, P30-CA015704-44, R50CA233042, T32 CA009515, P01CA077852, P30CA042014, P30CA15704, R01189184, R01CA194663, R01CA207371, R01CA220004, U01CA206110, U54CA143862
- Corr. Author:
- Authors:
- Lynn Symonds Ming Yu YuHong Zhang Fang-Shu Ou Tyler J. Zemla Kelly Carter Monica Bertagnolli Federico Innocenti Linda JW Bosch Gerrit A Meijer Beatriz Carvalho William M. Grady Stacey A. Cohen
- Networks:
- LAPS-MA036, LAPS-MN026, LAPS-NC007, NY167
- Study
- CALGB-89803
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- CALGB 89803 (Alliance), Epigenetic factors, DCR1, DNA methylation, biomarker, stage 3 colon cancer, response to irinotecan